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Abstract 
While thymopentin has been used for many years in the experimental treatment of Sézary 
syndrome (SS), a rare and very aggressive lymphoma, its mechanism of action is still not known. 
Herein we show that this peptide acts as an inhibitor of isolated iNOS and nNOS isoforms, and 
reduces iNOS protein/mRNA levels and iNOS activity in blood cells obtained from both healthy 
donors and SS patients. Similar results were obtained with TPN-2, the N-nitro analogue of the 
Arg-Lys motif present in thymopentin. Additional investigations are necessary to confirm the 
role and the relative importance of the two mechanisms of iNOS down-regulation in the 
therapeutic action of these peptides against SS. 
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1. Introduction 
Orphan diseases are diseases so rare that the interest of pharmaceutical companies in developing 
drugs for their treatment is limited, because of the lack of profit potential. The medicines used to 
manage these diseases are called orphan drugs, and their development is largely in the hands of 
academicians. According to the National Institutes of Health Office of Rare Diseases, about 6800 
such diseases are known to date [1,2]. Sézary syndrome (SS) is an example of orphan disease. SS 
is considered a rare and very aggressive leukemic variant of CTCL (cutaneous T cell 
lymphoma), characterized by extensive skin involvement (erythroderma), general 
lymphadenopathy, and by the presence of a malignant circulating T cell clone that over-
expresses CD60 and lacks CD26, CD7, and CD49 [3]. CTCLs are the most frequent form of 
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extranodal non-Hodgkin lymphomas (NHL), accounting for 0.5-3% of all NHLs [4]. SS is an 
aggressive disease with a poor prognosis, median survival being 2 to 4 years [5]. The aetiology 
of the disease is still largely unknown. Except for a small number of therapeutic agents 
(interferons), there are no reliable efficacy data on agents used to treat SS patients [6]. A better 
understanding of the immunopathogenesis of this disease could aid in finding a more effective 
therapy. SS is associated with significant immune abnormalities characterized by dysregulation 
of both cellular and humoral immunity. In general, a shift in cytokine response from Th1 to Th2 
is prominent in this disease, with concurrent down-regulation of IFN- and up-regulation of 
IL-10, IL-4 and IL-5. The latter are associated with defective neutrophil function and a reduction 
in cutaneous dendritic cells, as a result of the abnormal cytokine milieu [6]. Control of 
lymphocytic function and proliferation is of the utmost importance in the physiological balance 
of the immune system; alteration of this homeostasis may be important in the development of 
cancer or autoimmunity. 
Nitric oxide (NO) is a pleiotropic messenger produced from L-arginine by the enzyme 
NO-synthase (NOS). This enzyme exists in three distinct isoforms, eNOS, nNOS and iNOS. The 
first two are constitutive isoforms, while the third is an inducible isoform. NO is involved in a 
variety of physiological and pathological processes; it is also one of the final effectors in the 
immune system, where it is generated in large amounts (mM range) after induction of iNOS, in 
particular by macrophages. It diffuses into parasitic cells or into cancer cells, and kills them by 
producing reactive species and by inhibiting enzymes or other functional proteins [7,8]. In 
tumours, NO regulates a number of signalling pathways, and its effects are complex and closely 
dependent on concentration. A large body of experimental evidence demonstrates that NOS 
levels, in particular the iNOS level, are up-regulated in tumours [9,10]. This observation has led 
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to strategies aimed at blocking experimental tumour growth by using iNOS inhibitors [11,12]. 
NO is one of the most important factors involved: it regulates both the apoptosis of potential 
cancer cells and the responsiveness of lymphocytes to a certain antigen, as well as T lymphocyte 
proliferation and dendritic cell apoptosis [13,14]. Moreover, lymphocytes themselves have the 
potential to generate NO through iNOS activation, which in turn modulates apoptosis and 
cytokine production [15]. There is experimental evidence on animal models that T cell-
lymphoma tumour cells express large amounts of iNOS mRNA, and are characterized by high 
NO levels [16]. Conversely, it appears that iNOS may function as both an activator and an 
inhibitor of T cell apoptosis. In vitro, NO is capable of inducing apoptosis in cutaneous T cell 
lymphoma cells, by down-regulating NF-kB; therefore, it might act as a tumour suppressant [17].  
In general, very little is known about the role of iNOS and NO in SS and in NHL. Genetic 
polymorphism in NOS genes, together with environmental factors such as diet, seems to 
modulate the risk of developing NHL in humans [18]. Moreover, other genetic variants of 
oxidative stress genes are also associated with an increased risk of developing NHL [19]. 
Thymopentin (TP-5), a synthetic pentapeptide containing residues 32-36 of the thymic hormone 
thymopoietin (Fig. 1), triggers in vitro and in vivo immunomodulatory effects, and consequently 
it might be a useful agent in treating SS [20,21]. Indeed, in a study of 20 patients with Sézary 
syndrome, Bernengo et al. observed that treatment with TP-5 produced eight complete and seven 
partial remissions [22]; these responses were achieved when circulating Sézary cells were below 
2600 mm-3. The mechanism of action of this peptide remains largely unknown. 
This paper describes the results of a study carried out on TP-5, and shows this peptide to be an 
inhibitor of iNOS and, less effectively, of nNOS recombinant enzymes. In addition, we show that 
it is able to down-regulate the expression of iNOS mRNA/protein, as well as iNOS activity in the 
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peripheral blood adherent mononuclear cells (PBAMCs) of SS patients. The behaviour of some 
shorter peptides, TP-2, TP-3, TP-4, and of the analogues TPN-2, TPN-3, TPN-4, TPN-5, in 
which L-arginine is replaced by N-nitro-L-arginine (Scheme 1), was also studied, for 
comparison purposes. 
 
2. Materials and methods 
2.1. Synthesis 
N-Fmoc-protected amino acids, O-benzotriazole-N,N,N',N'-tetramethyluronium 
hexafluorophosphate (HBTU), hydroxybenzotriazole (HOBt), 4-dimethylaminopyridine 
(DMAP) and Wang resin were purchased from GL Biochem (Shanghai, China). N-Boc-
N-nitro-L-arginine was purchased from Fluka (Buchs, Switzerland). All reagents and CH3CN 
for HPLC were analytical grade and used without further purification. The peptides subject of 
this study were synthesised manually in a stepwise fashion via the solid-phase method [23], 
using a reaction vessel equipped with gas and solvent inlets/outlets; the contents were stirred by 
streaming a gentle nitrogen flux through the resin bed. HBTU and HOBt were used as coupling 
agents, in the presence of N,N-diisopropylethylamine (DIEA); the C-terminal amino acid was 
coupled to Wang resin (0.3 g, 1.3 mmol of NH2 groups g
-1) under the same conditions, plus a 
catalytic amount of DMAP. The N-Fmoc protecting groups were removed by treating the 
protected resin-bound peptide with 25% piperidine in DMF (10 mL for 5 min, then 10 mL for 20 
min). After washing with DMF (310 mL), synthesis proceeded to the next coupling step. A 
threefold excess of amino acid and coupling agents was used at each coupling step, to ensure 
completion of the reaction, which was routinely checked by the Kaiser test [24] on a few resin 
beads. Excess reagents were then washed with DMF (310 mL), CH2Cl2 (410 mL), and the 
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Fmoc deprotection protocol was repeated. After the last amino acid had been coupled, the 
N-terminal Fmoc group was removed as described above, then the peptide was released from the 
resin by treatment with TFA/Et3SiH/H2O (90:5:5) for 3 h. The resin was vacuum filtered, and the 
crude peptide was precipitated from the filtrate with cold anhydrous ethyl ether. All products 
were purified by RP-HPLC on a semi-preparative C18-bonded silica column (Vydac 
218TP1010, 1.025 cm) using a gradient of CH3CN in 0.1% aqueous TFA (from 10% to 50% in 
45 min) at a flow rate of 1.0 mL min-1. Title compounds were obtained as white solids by freeze-
drying the appropriate fractions after removal of CH3CN by rotary evaporation. Structures were 
confirmed by mass and NMR spectrometry, and purity of synthesized peptides was assessed as 
>99% by analytical RP-HPLC. Elemental analyses were performed by REDOX s.n.c. (Monza, 
Italy) and were within ±0.4% of the theoretical values. 1H-NMR, 13C-NMR and elemental 
compositions (C, H, N) are available as Supplementary material. 
2.2. Cell sources and cultures 
PBAMCs were obtained from ten healthy donors and from two Sèzary syndrome patients with 
circulating atypical T cells (CD4+ CD26-). The study was conducted in accordance with the 
Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments 
involving humans, and was approved by our ethical committee. All subjects gave their signed 
informed consent to participate in the study. PBAMCs were isolated by Ficoll-Hypaque density 
gradient centrifugation. Isolation and purification of PBAMCs exploited their adherence to 
culture plates: after 1 h at 37 °C, non-adherent cells were removed with the supernatant, then 
washed three times with phosphate buffer solution. Adherent cells (more than 90% of which 
were CD14+) were carefully detached from the surface of the culture plates and re-suspended 
in RPMI 1640 medium supplemented with 10% fetal calf serum, 4 mM L-glutamine, 25 mM 
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Hepes buffer, 50 U mL-1 penicillin, and 50 mg mL-1 streptomycin; all media and components 
were purchased from SIGMA (Italy). Cells (106 mL-1) were immediately plated and incubated at 
37 °C in a cell culture incubator under a 95% humidified 5% CO2 atmosphere. 
2.3. Cell stimulation 
The PBAMCs obtained from each subject, prepared following the same experimental procedure, 
were rinsed with fresh medium and stimulated with an inflammatory stimulant comprising LPS 
(10 g mL-1) and IFN- (100 U mL-1), in the presence or in the absence of the test compound 
(100 M). This concentration of the peptides was selected based on the results of pilot studies, 
using three different concentrations of the inhibitor (50, 100, 150 M; data not shown). The test 
compounds were dissolved in sterile distilled water and added to cell cultures. An equal volume 
of medium was added to controls to normalize volumes. Prior to use, all reagents were tested for 
endotoxin (< 10 pg mL-1; Associates of Cape Cod, Inc., Woods Hole, MA, USA) and 
mycoplasma contamination (General-probe II; General-probe Inc., San Diego, CA, USA) and 
found negative. The same batch of serum and of medium was used in all experiments. Cell 
viability in each culture was assessed by Trypan blue exclusion. Cytotoxicity experiments were 
performed using Cytotox 96 (Promega, Southampton, UK). 
2.4. NOS activity 
NOS activity was monitored using a hemoglobin capture assay [25]. A typical assay mixture for 
NOS contained 20 M L-arginine, 100 M NADPH, 10 M tetrahydrobiopterin, 100 M 
dithiothreitol, 1.6 mM CaCl2, 11.6 mg mL
-1 calmodulin, 3 mM oxyhemoglobin, plus the test 
concentration of inhibitor in 100 mM HEPES (pH 7.5). iNOS activity was assessed as described 
above, but in calcium-free conditions. All assays were carried out in a final volume of 1 mL and 
were initiated with enzyme. Nitric oxide reacts with oxyhemoglobin to yield methemoglobin, 
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which was detected at 401 nm (ε = 19,700 M-1 cm-1) on a Perkin-Elmer LambdaBIO UV-vis 
spectrophotometer and recorded over 1 min. In addition, 50 units each of SOD and CAT were 
included in all assays, to minimize interference from reactive oxygen species, namely O2
- and 
H2O2. All assays were performed at 37 °C and the results shown are the mean of three 
experiments. Cellular iNOS inhibitory activity was determined in the 11,000g supernatant of 
PBAMC homogenates. To ensure that the observed conversion of oxyhemoglobin to 
methemoglobin was amenable to NOS activity the hemoglobin capture assay was also repeated 
under the conditions described by Salter and Knowles [26]. Enzyme kinetic experiments were 
performed with recombinant enzymes. The NOS isoforms used were: iNOS (murine 
recombinant) expressed in E. coli, eNOS (bovine recombinant) isolated from a baculovirus 
overexpression system in Sf9 cells, and nNOS (rat recombinant) isolated from the baculovirus 
expression system in Sf21 cells. 
The corresponding Ki values of TP-5 and TPN-2 inhibitors were calculated from the IC50 values 
via Eq. 1, using Km values determined by the oxyhemoglobin assay over a range of arginine and 
peptide concentrations (murine iNOS: 16 M). 
Ki = IC50 / (1 + S / Km)        (1) 
2.5. Western blotting 
Western blotting was accomplished according to standard procedures. Total proteins were 
obtained using a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 0.4% Nonidet P-40, 120 mM 
NaCl, 1.5 mM MgCl2, 2 mM phenylmethylsulfonyl fluoride, 80 lg/mL of leupeptin, 3 mM NaF 
and 1 mM DTT at 4° C for 30 min. Cell lysates (50 mg of total protein) were resolved on a 
4-12% NuPAGE gradient gel (Invitrogen), then electrotransferred onto a nitrocellulose 
membrane. Nitrocellulose was blocked in Tris-Buffered Saline (TBS)-milk and incubated 
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overnight with an anti-iNOS primary antibody (1:1000) (Santa Cruz Biotech Inc., Santa Cruz, 
CA, USA). Nitrocellulose sheets were then washed in TBS, incubated for 1 h with a secondary 
antibody conjugated with alkaline phosphatase, washed again, and developed in an alkaline 
buffer with nitroblue-tetrazolium (NBT) as substrate (Alkaline Phosphatase Conjugate Substrate 
Kit, Bio-Rad, Hercules, CA, USA). -actin (1/10.000; Sigma, Italy) was used as internal 
standard. The resulting blot image files were imported and analysed with a commercially 
available gel-analysis software package (Gel Doc 1000 Bio-Rad, Milan, Italy). 
2.6. Semi-quantitative reverse transcription-polymerase chain reaction 
RT-PCR was used to determine iNOS mRNA levels in PBAMCs. Total RNA was extracted 
using 1 mL g-1 ULTRASPEC-RNA (Biotech Lab. Inc., Houston, TX, USA), as recommended by 
the manufacturer. RNA was dissolved in diethyl pyrocarbonate (DEPC)-treated water and 
quantified spectrophotometrically at 260 nm. First-strand cDNA was generated by adding RNA 
(1 g) to a mixture containing 1 mM deoxy-nucleoside-triphosphate (dNTP), 1 U L-1 RNase 
inhibitor, 2.5 U L-1 Moloney murine leukemia virus reverse transcriptase, 2.5 M oligo-dT, 5 
mM MgCl2, and 10X PCR buffer, to a final volume of 20 L. Reverse transcription was run at 
42 °C for 1 h followed by heat inactivation of reverse transcriptase at 92 °C for 10 min. 
Ribosomal mRNA (18S) was employed as internal standard and was amplified from the same 
amount of RNA, to correct for variations among different samples. PCR amplification was 
performed using a Programmable Thermal Controller (MJ Research Inc., MA, USA). The PCR 
solution contained 10 L of first-strand cDNA, 4 L 10X PCR buffer, 2 mM MgCl2, 2 U mL-1 
Termophylus aquaticus (Taq) DNA polymerase (Celbio, Milan, Italy), and water, to a final 
volume of 50 L. The following primer pairs (MWG-Biotech AG, Italy) were used: sense 5’-
CGT AAA GAC CTC TAT GCC AA-3’ and antisense 5’-AGC CAT GCC AAA TGT CTC AT-
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3’ for iNOS and 18S primers, 0.15 mM of both sense 5’-TAC GGA GCA GCA AAT CCA C-3’ 
and antisense 5’-GAT CAA AGG ACT GCA GCC TG-3’. Samples were overlaid with mineral 
oil and subjected to 30 cycles at 95 °C for 60 s, 60 °C for 60 s, and to one cycle at 72 °C for 7 
min. PCR products were run on 2% agarose gel electrophoresis and photographed after ethidium 
bromide staining under UV light. Bands on the gel were scanned using a computerised 
densitometric system (Bio-Rad Gel Doc 1000, Milan, Italy). Data are expressed as mean±SD 
intensity of optical density. 
2.7. Statistical analyses 
Data are given as mean±standard deviation (SD) of at least three separate experiments. In the 
figures, SD are indicated by vertical bars. Statistical analysis was done by One-Way analysis of 
variance (ANOVA) with Dunnett's post-hoc test where applicable, using GraphPad Prism 
version 4 (GraphPad Software, San Diego, USA). ** denotes a p-value < 0.01, * denotes a 
p-value < 0.05 and p-values greater than 0.05 were deemed not significant. 
2.8. Molecular modeling 
Molecular models of TP-5 and TPN-2 were built with MOE [27]. The coordinates of the TP-5 
peptide were modelled upon those of the RGDVY fragment of the HLA-DQ protein, whose 
crystallographic structure was retrieved from the Protein Data Bank (PDB ID: 3PL6) [28]. A 
conformational search on TPN-2 was carried out with the LowModeMD method [29], simulating 
the solvent implicitly with the GB/SA model. The most stable conformations in a 1-kcal range 
from the global minimum were rigidly superimposed on the TP-5 template using a best-fit 
algorithm as implemented in the Open3DALIGN software [30]. 
 
3. Results and discussion 
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Peptides were synthesized via a solid-phase approach, using the standard Fmoc method in a 
manual reaction vessel (see Materials and Methods for details). Firstly, all products were tested 
for their ability to inhibit the production of NO from L-arginine by the three NOS isoforms, 
using an enzymatic assay [25]. Recombinant enzymes from different sources were used, namely 
murine macrophage iNOS, rat brain nNOS, and bovine eNOS. The inhibitory activity against 
NOS isoforms was assessed by monitoring the oxidation of oxyhemoglobin to methemoglobin 
by NO. Table 1 lists the potencies of the products expressed as IC50, namely the concentration 
able to reduce by 50% the NOS-induced production of NO by L-arginine; selectivity among 
isoforms is also reported. To confirm that the conversion of oxyhemoglobin to methemoglobin 
was actually due to NOS activity, the hemoglobin capture assay was also performed as described 
by Salter and Knowles [26], finding almost identical results (data not shown). 
TP-5 is the most active member of the TP series: it inhibits iNOS in the micromolar range 
(IC50 = 15 M), being a 4-times less potent inhibitor of nNOS (IC50 = 60 M), and a very weak 
inhibitor of eNOS. The tetrapeptide TP-4 has a low inhibitory potency against both the eNOS 
and the nNOS isoforms, while it is only half as potent as the lead compound against iNOS 
(IC50 = 30 M). The shorter peptides TP-2 and TP-3 display very feeble inhibitory activity 
against all isoforms. All peptides belonging to the N-nitro-L-arginine series (TPN) display very 
poor inhibitory activity against the eNOS isoform, similarly to their TP analogues, but their 
behaviour versus both iNOS and nNOS differs to some extent. In particular, TPN-5 (IC50 = 15 
M) is an inhibitor of iNOS as potent as TP-5, while it displays lower iNOS/nNOS selectivity, 
since it inhibits nNOS three times as strongly as TP-5. TPN-4 behaves similarly to TP-4. TPN-2 
(IC50 = 5 M) and TPN-3 (IC50 = 10 M) were the most active compounds against iNOS: TPN-2 
was three times more active than TP-5 and double than TPN-3, whereas their iNOS/nNOS 
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selectivity was similar. The type of inhibition elicited by TP-5 and TPN-2 was also investigated. 
Both peptides are competitive inhibitors of iNOS, inhibiting binding of the substrate L-arginine 
to murine macrophage iNOS with a Ki of 6.7 M for TP-5 and 2.2 M for TPN-2. The rate of 
enzyme activity decreases with increasing concentrations of the two peptides, but it remains 
constant over time (Fig. 2; only data for TP-5 are shown). Reversible inhibition of murine iNOS 
enzyme activity was assessed for both peptides, by re-determining iNOS activity after their 
removal by dialysis. Subsequently, the effect of TP and TPN peptides on PBAMCs derived from 
blood of healthy donors was evaluated. None of the peptides caused significantly increased cell 
death versus untreated cells; levels of LDH released following treatment were comparable to 
those measured in untreated control samples. Also in this case, iNOS inhibitory activity by the 
peptides was studied via the oxyhemoglobin assay. PBAMCs were treated with peptide (100 
M) for 1 h, then iNOS activity and expression were induced by 24-h incubation with LPS (10 
g mL-1) and IFN- (100 U mL-1); enzymatic activities in the absence of peptide, with and 
without LPS/IFN- stimulation, are reported as controls (Fig. 3A). 
In the TP series, TP-2, TP-3, and TP-4 displayed similar activities (roughly 50% inhibition of 
NO production), while TP-5 elicited the highest degree of inhibition (80%). Among TPN 
analogues, TPN-2 was the most effective (44% inhibition), while TPN-3, TPN-4 and TPN-5 did 
not decrease iNOS activity. This is surprising in view of the products’ ability to inhibit the 
isolated iNOS isoform, and to reduce iNOS mRNA and iNOS protein expression levels in cells 
to some extent (see below; Fig. 3B and 3C). Multiple mechanisms control the expression and the 
activity of NOS isoforms. Although iNOS activity is independent of calcium concentrations, 
many other specific intracellular regulatory mechanisms might enhance iNOS enzyme activity 
for TPN-3, TPN-4 and TPN-5. Indeed, one of the post-translational steps converting NOS 
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polypeptides into the active enzymes is the process of iNOS homodimerization, which in turn is 
influenced by the availability of its own substrates and co-factors [31]. Studies are in progress in 
our laboratory to strengthen these preliminary observations and to confirm this hypothesis. 
In order to determine whether the modulation of iNOS activity is also related to its expression, 
the effects of the TP and TPN series on iNOS protein and mRNA levels in LPS/IFN--stimulated 
cells were examined. Cells were cultured alone, or in the presence of peptide, then pre-incubated 
at 100 M 1 h before the 24-h treatment with LPS/IFN-. Immunoblotting evidenced a band with 
an estimated molecular mass of 130 kDa, corresponding to the iNOS protein (Fig. 3B). All the 
products reduced iNOS protein levels compared to control cells; however, the extent of reduction 
varied across the series. In the TP series, the effect shows an increasing trend with increasing 
length of the peptide chain, the most active product being TP-5. This compound reduces iNOS 
protein expression (p < 0.01) by about 45%, while the shortest member of the series TP-2 only 
reduces it by 15%, with less statistical significance (p < 0.05). By contrast, in the TPN series the 
trend is reversed, the most active product being TPN-2 and the least active TPN-5; these have 
comparable activity to TP-5 and to TP-2, respectively.  
Since the Western blot analyses indicated that the peptides were able to counteract iNOS 
overexpression induced by LPS/IFN-, semi-quantitative reverse-transcribed polymerase chain 
reaction (RT-PCR) was performed to check whether iNOS mRNA levels were also affected. 
Total RNA was extracted from PBAMCs and subjected to RT-PCR. The PCR products were 
separated by agarose gel electrophoresis, and photographed after ethidium bromide staining 
under UV light. The detected mRNA levels are reported in Fig. 3C. All products, tested at 100 
M, decreased mRNA levels compared to control cells, although with different statistical 
significances. The trend of the activity in the TP series parallels the one found for iNOS protein 
15 
 
level reduction. Again, the most active product was TP-5 (about 50% reduction of mRNA level, 
p < 0.01), and the least active was TP-2 (about 25% reduction of mRNA level, p < 0.05). In the 
TPN series, the parallelism was looser: the shortest member, TPN-2, was the most effective 
(about 50% reduction of mRNA level, p < 0.01), while the other peptides all had similar 
activities (about 24% reduction of mRNA level, p < 0.05). In summary, TP-5 and TPN-2 
exhibited the most potent inhibitory effect on iNOS activity and expression. As shown in Fig. 4, 
both peptides displayed respectively similar (TPN-2) and significantly greater (TP-5) ability to 
decrease iNOS activity and expression compared to the positive control L-NAME (100 M). 
Finally, the down-regulating effect on iNOS of TP-5 and TPN-2 was investigated in ex vivo 
PBAMCs isolated from two patients affected by SS syndrome, who displayed a significantly 
higher basal iNOS level compared to healthy subjects (patient 1: 0.46±0.01; patient 2: 0.54±0.01; 
healthy subjects 0.22±0.02; p < 0.01). Following incubation over 24 h at three different 
concentrations (1, 10, 100 M), both peptides triggered a reduction of iNOS protein levels, as 
determined by immunoblotting (Fig. 5A). TP-5 had a significant effect at 10 and 100 M (at 10 
M, patient 1: 0.22±0.01; patient 2: 0.20±0.06, respectively); TPN-2 was similarly active, but 
already influenced the iNOS level at a concentration as low as 1 M (patient 1: 0.23±0.01; 
patient 2: 0.26±0.02, respectively). Subsequently, we used the oxyhemoglobin assay to assess 
whether inhibition of iNOS protein expression by the two peptides was accompanied by a 
parallel change in NO production. Both peptides were able to decrease iNOS activity, TP-5 being 
slightly more potent (Fig. 5B). 
In the attempt to clarify whether a stereoelectronic similarity might underlie the comparable 
activity profiles of TP-5 and TPN-2, the three-dimensional structure of TP-5 (amino acid 
sequence RKDVY) was modeled upon the RGDVY motif present in the HLA-DQ protein, 
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whose crystallographic coordinates are available in the Protein Data Bank. The choice of the 
template was based on the relationship between thymopentin and the RGDVY fragment 
established by previous investigators [32]; the resulting conformation is in accordance with 
evidences gathered from NMR studies [33]. Subsequently, a conformational search on TPN-2 
was carried out, and the most stable conformers underwent rigid-body superimposition on the 
TP-5 scaffold. The best-fitting conformation of TPN-2 shows an excellent match with TP-5, 
namely between the Lys side chains and the charged terminal amino groups; interestingly, the 
N-nitro moiety of TPN-2 appears to mimic the carboxylate group of the Asp residue in TP-5 
(Fig. 6). The synthesis of opportunely constrained analogues is necessary to confirm the role of 
these pharmacophoric features in the activity of the two peptides. 
 
4. Conclusions 
Despite the fact that thymopentin has been used successfully for many years in the experimental 
treatment of Sézary syndrome, its mechanism of action has remained obscure. In this study we 
demonstrate that this peptide acts as an inhibitor of the isolated recombinant iNOS and nNOS 
isoforms, and reduces iNOS protein/mRNA levels and iNOS activity in PBAMCs of both 
healthy donors and SS patients. Results with TPN-2, the N-nitro analogue of the Arg-Lys motif 
present in TP-5, were similar. The preliminary assays performed so far could not indicate the 
individual contribution of the two mechanisms of iNOS down-regulation to the overall inhibitory 
effect in cells. To shed light on this point, additional investigations are necessary, including the 
assessment of the degree of penetration of these peptides in the cells, and the identification of the 
intracellular pathways and the transcription factors involved in the reduction of protein 
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expression. These studies will allow saying a conclusive word about the role of iNOS down-
regulation in the therapeutic action of TP-5 against SS. 
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Fig. 1. Sequences of the synthesised peptides. 
 
 
Fig. 2. Time course of murine macrophage iNOS inhibition elicited by TP-5 at increasing 
concentrations vs control (iNOS). 
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Fig. 3. A) Percentage of cellular iNOS activity compared to untreated samples (control) and to 
samples stimulated with LPS/INF-, in the absence (LPS+INF-) and in the presence of TP/TPN 
peptides. (** p < 0.01, *p < 0.05; Dunnett’s test vs LPS+INF-). B) Effects of iNOS protein 
expression in PBAMCs compared to untreated samples (control) and to samples stimulated with 
LPS/INF-, in the absence (LPS+INF-) and in the presence of TP/TPN peptides. The Western 
blot reported in figure is representative of five independent experiments performed, which all 
gave similar results. In the densitometric analysis, each bar represents the mean intensity of 
optical density (IOD)SD of relative expression of iNOS, normalized to -actin level 
(** p<0.01, * p<0.05; Dunnett’s test vs LPS+INF-). C) RT-PCR analysis of iNOS mRNA 
expression level in PBAMCs compared to untreated samples (control) and to samples stimulated 
with LPS/INF-, in the absence and in the presence of TP/TPN peptides. The gel shown in figure 
is representative of three independent experiments performed. In the densitometric analysis, each 
bar represents the mean IODSD of the relative expression of iNOS normalized to 18S level 
(** p < 0.01, * p < 0.05; Dunnett’s test vs LPS+INF-). 
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Fig. 4. A) Percentage of cellular iNOS activity compared to untreated samples (control) and to 
samples stimulated with LPS/INF-, in the absence (LPS+INF-) and in the presence of TP-5 and 
TPN-2 peptides. (* p < 0.05; Dunnett’s test vs LPS+INF-). B) Effects of iNOS protein 
expression in PBAMCs compared to untreated samples (control) and to samples stimulated with 
LPS/INF-, in the absence (LPS+INF-) and in the presence of TP-5 and TPN-2 peptides. The 
Western blot reported in figure is representative of three independent experiments performed, 
which all gave similar results. In the densitometric analysis, each bar represents the mean 
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IODSD of the relative expression of iNOS normalized to -actin level (** p < 0.01, * p < 0.05; 
Dunnett’s test vs LPS+INF-). 
 
 
Fig. 5. PBAMCs of two SS patients (black and gray histograms, respectively) were treated ex 
vivo with different concentrations of TP-5 and TPN-2 peptides; healthy subjects (HS, white 
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histogram) and untreated PBAMCs (basal) are reported as controls. Values are meanSD of 
different experiments performed in triplicate (** p < 0.01, * p < 0.05; Dunnett’s test vs basal). A) 
Effects on relative expression of iNOS, normalized to -actin level. The Western blot reported is 
representative of three independent experiments performed. In the densitometric analysis, each 
bar represents the mean IODSD of relative expression of iNOS normalized to -actin level. B) 
Effects on iNOS activity. 
 
 
Fig. 6. TP-5 conformation modeled on the RGDVY motif present in the HLA-DQ protein 
(thicker sticks), superimposed on the best-matching TPN-2 conformation (thinner sticks). 
